Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TB or not TB: Is Emergent‘s vaccine the solution?

This article was originally published in Scrip

Executive Summary

MVA85A, the leading investigational vaccine against TB, has failed to replicate early promising efficacy seen in adults in a new Phase IIb study in infants published this week in The Lancet. But despite the disappointment, experts say this should not spell the end for the product, and the study should provide useful pointers for planning other trials and vaccination strategies.

Advertisement

Related Content

Promising Results In GSK Study Could Break Years Of TB Vaccine Deadlock

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC020304

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel